| Literature DB >> 32329971 |
Melissa M Arons1, Kelly M Hatfield1, Sujan C Reddy1, Anne Kimball1, Allison James1, Jesica R Jacobs1, Joanne Taylor1, Kevin Spicer1, Ana C Bardossy1, Lisa P Oakley1, Sukarma Tanwar1, Jonathan W Dyal1, Josh Harney1, Zeshan Chisty1, Jeneita M Bell1, Mark Methner1, Prabasaj Paul1, Christina M Carlson1, Heather P McLaughlin1, Natalie Thornburg1, Suxiang Tong1, Azaibi Tamin1, Ying Tao1, Anna Uehara1, Jennifer Harcourt1, Shauna Clark1, Claire Brostrom-Smith1, Libby C Page1, Meagan Kay1, James Lewis1, Patty Montgomery1, Nimalie D Stone1, Thomas A Clark1, Margaret A Honein1, Jeffrey S Duchin1, John A Jernigan1.
Abstract
BACKGROUND: Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection can spread rapidly within skilled nursing facilities. After identification of a case of Covid-19 in a skilled nursing facility, we assessed transmission and evaluated the adequacy of symptom-based screening to identify infections in residents.Entities:
Mesh:
Year: 2020 PMID: 32329971 PMCID: PMC7200056 DOI: 10.1056/NEJMoa2008457
Source DB: PubMed Journal: N Engl J Med ISSN: 0028-4793 Impact factor: 91.245
Figure 1Residents in Facility A on March 3 through Two Point-Prevalence Surveys.
Shown are all 89 residents who lived in skilled nursing facility A from March 3, when the first resident tested positive for SARS-CoV-2. By March 13, the date of the first point-prevalence survey, 82 residents remained in the facility, and 76 were tested. By the second point-prevalence survey, 48 of the 76 residents tested in the point-prevalence surveys had been identified as positive. Overall, 57 residents were positive as of March 26. Cycle threshold values were available for 47 residents who tested positive in the point-prevalence surveys on March 13 and March 19–20.
Demographic Characteristics and Reported Symptoms in Residents of Facility A at the Time of Testing.*
| Characteristics | SARS-CoV-2 Test Results | |
|---|---|---|
| Positive | Negative | |
| Positive result during initial facility-wide cohort testing — no. (%) | 23 (48) | — |
| Mean age (±SD) — yr | 78.6±9.5 | 73.8±11.5 |
| Length of stay at Facility A <90 days before testing — no. (%) | 23 (48) | 14 (50) |
| Any coexisting condition | 47 (98) | 28 (100) |
| Chronic lung disease | 18 (38) | 8 (29) |
| Diabetes | 18 (38) | 11 (39) |
| Cardiovascular disease | 39 (81) | 17 (61) |
| Cerebrovascular accident | 19 (40) | 8 (29) |
| Renal disease | 18 (38) | 9 (32) |
| Received hemodialysis | 3 (6) | 1 (4) |
| Cognitive impairment | 28 (58) | 13 (46) |
| Obesity | 11 (23) | 6 (21) |
| In symptomatic residents | 21 (44) | 11 (39) |
| At least one typical Covid-19 symptom | 17 (35) | 8 (29) |
| Only atypical Covid-19 symptoms | 4 (8) | 3 (11) |
| In asymptomatic residents | 27 (56) | 18 (64) |
| No symptoms | 15 (31) | 14 (50) |
| Only stable, chronic symptoms | 12 (25) | 3 (11) |
Results include all residents who were present in the facility on March 13 and assented to screening. Facility-wide cohort symptom screens and point-prevalence surveys were performed on March 13 and March 19–20, 2020.
Residents categorized as positive include those with at least one positive test from facility-wide point-prevalence surveys on March 13 or March 19–20 and one resident who tested negative on March 13 but tested positive before March 13.
Residents categorized as negative include 3 residents who had only one negative swab on March 13 and were not retested.
Typical symptoms include fever, cough, and shortness of breath. Atypical symptoms include chills, malaise, sore throat, increased confusion, rhinorrhea or nasal congestion, myalgia, dizziness, headache, nausea, and diarrhea.
Figure 2Cycle Threshold Values and Results of Viral Culture for Residents with Positive SARS-CoV-2 Tests According to Their Symptom Status.
Shown are N1 target cycle threshold values and viral culture results for 47 residents’ first positive test for SARS-CoV-2 stratified by the resident’s symptom status at the time of the test. One positive test was not assessed for culture growth. Typical symptoms include fever, cough, and shortness of breath; atypical symptoms include chills, malaise, increased confusion, rhinorrhea or nasal congestion, myalgia, dizziness, headache, nausea, and diarrhea.
Figure 3Cycle Threshold Values Relative to First Evidence of Fever, Cough, or Shortness of Breath.
Shown are N1 target cycle threshold values and viral culture results for each resident’s positive tests for SARS-CoV-2 shown by day since the first evidence of fever, cough, or shortness of breath (N=55). Dates of onset of typical symptoms were known for 43 residents; 12 residents with two specimens that were positive for SARS-CoV-2 are also included. One positive test was not assessed for culture growth. The relationship between the first test and the second test for residents who had two positive tests is shown in Figure S2.
Figure 4Timeline Showing Prevalence, Notable Events, and Implementation of Infection Prevention and Control Measures at Facility A.
Dashed lines indicate the prevalence of Covid-19 based on test results obtained during clinical evaluation of symptomatic residents before a unit-wide or facility-wide point-prevalence survey (PPS); the dotted line indicates the prevalence based on results from a unit-specific point-prevalence survey; and solid lines indicate the prevalence based on results from clinical evaluation and a facility-wide point-prevalence survey. PPE denotes personal protective equipment.